Shaikh Safiya I, Revur Laksmi R, Mallappa Marutheesh
Department of Anaesthesia, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India.
Anesth Essays Res. 2017 Apr-Jun;11(2):503-507. doi: 10.4103/aer.AER_255_16.
Epidural administrations of α2 agonists are being used as adjuvants as they lead to anxiolysis, sedation, analgesia, and hypnosis.
This study aims to evaluate the analgesic effects of epidural α2 agonists-dexmedetomidine and clonidine in conjunction with intrathecal levobupivacaine in combined spinal epidural anesthesia (CSEA).
A prospective, randomized controlled study was done to assess and compare the efficacy and clinical profile of two α2 adrenergic agonists, clonidine, and dexmedetomidine administered epidurally in combination with intrathecal levobupivacaine in CSEA. The study was conducted for 1 year. Sixty adult patients physical status Class I and II undergoing below umbilical surgeries under CSEA were included in the study after a valid consent. Patients were randomly assigned into two groups, to receive either epidural dexmedetomidine (1.5 μg/kg) or clonidine (2 μg/kg) in 10 ml normal saline along with 0.5% isobaric levobupivacaine 15 mg (3 ml). Block characteristics, ability to provide sedation, duration, and quality of analgesia and side effects were studied and compared between the groups.
The characteristics of intraoperative block were comparable among two groups. As compared to clonidine, dexmedetomidine provided a better sedation and prolonged analgesia, evidenced by the distribution of visual analog scale scores and requirement rescue analgesic among two groups. The side effect profile of the two drugs was comparable.
Dexmedetomidine at 1.5 μg/kg epidurally with intrathecal levobupivacaine is a better adjuvant compared to clonidine at 2 μg/kg epidurally in CSEA because of better sedation, prolonged analgesia, and safe side-effect profile.
硬膜外给予α2激动剂作为辅助用药,因其可产生抗焦虑、镇静、镇痛和催眠作用。
本研究旨在评估硬膜外α2激动剂右美托咪定和可乐定联合鞘内注射左旋布比卡因用于腰麻-硬膜外联合麻醉(CSEA)时的镇痛效果。
进行一项前瞻性随机对照研究,以评估和比较两种α2肾上腺素能激动剂可乐定和右美托咪定硬膜外联合鞘内注射左旋布比卡因在CSEA中的疗效和临床特征。研究持续1年。60例美国麻醉医师协会身体状况分级为Ⅰ级和Ⅱ级、接受脐以下手术的成年患者在签署有效知情同意书后纳入研究。患者随机分为两组,分别接受10 ml生理盐水中含硬膜外右美托咪定(1.5 μg/kg)或可乐定(2 μg/kg),以及0.5%等比重左旋布比卡因15 mg(3 ml)。研究并比较两组之间的阻滞特征、镇静能力、镇痛持续时间和质量以及副作用。
两组术中阻滞特征相当。与可乐定相比,右美托咪定的镇静效果更好,镇痛时间更长,这在两组视觉模拟量表评分分布和补救性镇痛药物需求方面得到证实。两种药物的副作用情况相当。
在CSEA中,与硬膜外给予2 μg/kg可乐定相比,硬膜外给予1.5 μg/kg右美托咪定联合鞘内注射左旋布比卡因是更好的辅助用药,因为其镇静效果更好、镇痛时间更长且副作用安全。